Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-29
2006-08-29
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S469000
Reexamination Certificate
active
07098232
ABSTRACT:
The present invention provides a method for preventing and treating gastrointestinal diseases such as dyspepsia, irritable bowel disease and chemotherapy-associated nausea by administering an antagonist or partial agonist of 5HT1a receptors.
REFERENCES:
patent: 5403848 (1995-04-01), Dinan et al.
patent: 5859065 (1999-01-01), Brandes
patent: 6159979 (2000-12-01), Gaster et al.
patent: RO 92436 (1987-09-01), None
Fisher, R. S. et al., “Management of Nonulcer Dyspepsia,”The New England Journal of Medicine, vol. 339, pp. 1376-1381, 1998.
Brown, C. et a., “Dyspepsia in General Practice,”BMJ, vol. 200, pp. 829-830, 1990.
Nyréen, O. et al., “Excess Sick-Listing in Nonulcer Dyspepsia, ”Journal of Clinical Gastroenterology, vol. 8, pp. 339-345, 1986.
Thakore, J. H. et al., “Treating Depression with SPecific Serotonergic Acting Agents,”Journal of Serotonin Research, vol. 3, pp. 145-160, 1996.
Talley, N. J. et al., “Dyspepsia and Dyspepsia Subgroups: A Population-Based Study,”Gastroenterology, vol. 102, pp. 1259-1268, 1992.
Talley, N. J. et al., “Non-Ulcer Dyspepsia: Potential Causes and Pathophysiology,”Annals of Internal Medicine,vol. 108, pp. 865-879, 1988.
Dotevall, G., “Psychosomatic Gastroenterlogy Today and Some Ideas for Tomorrow,”Gastroenterol International,vol. 2, pp. 96-100, 1989.
Gershon, M. D., “The Nervous System of the Gut,”Gastroenterology, vol. 80, pp. 1571-1594, 1981.
Baumgarten, H. G., “Neuroanatomy and Neurophysiology of Central Serotonergic Systems,”Journal of Serotonin Research, vol. 3, pp. 171-179, 1994.
Lundgren, O. et al., “Enteric Nervous System: I. Physiology and Pathophysiology of the Intestinal Tract,”Digestive Diseases and Sciences, vol. 34, pp. 264-283, 1989.
Rowland, N. et al. “Inhibition of Gastric Emptying by Peripheral and Central Fenfluramine in Rats: Correlation with Anorexia,”Life Sciences, vol. 34, pp. 2495-2499, 1984.
Talley, N. J. et al., “Functional Dyspepsia: A Classification with Guidelines for Diagnosis and Management,” Gastoenterology International, vol. 4, pp. 145-160, 1991.
Dinan, T. G. et al., “Serotonin Sypersensitivity: The Pathophysiologic Basis of Non-Ulcer Dyspepsia?”Scandinavian Journal of Gastroenterology, vol. 25, pp. 541-544, 1990.
Chua, A. et al., “Central Serotonin Receptors and Delayed Gastric Emptying in Non-Ulcer Dyspepsia,” BMJ, vol. 305, pp. 280-282, 1992.
Lamberts, S. W. J., “Regulation of Prolactin Secretion at the Level of the Lactotroph,”Physiological Reviewsvol. 70, pp. 279-318, 1990.
Meltzer, H. Y. et al., “Effects of Buspirone on Plasma Prolactin and Cortisol Levels in Major Depressed and Normal Subjects,”Society of Biological Psychiatry, vol. 35, pp. 316-323, 1994.
Corradetti, R. et al., “Antagonist Properties of (-)-pindolol and WAY 100635 at Somatodendritic and Postsynaptic 5-HT1AReceptors in the Rat Brain,”British Journal of Pharmacology, vol. 123, pp. 449-462, 1998.
Dinan Timothy G.
Keeling Patrick W. N.
Athpharma Limited
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Jagoe Donna
Low Christopher S. F.
LandOfFree
Treatment and prevention of gastrointestinal disease using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of gastrointestinal disease using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of gastrointestinal disease using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636097